Seromycin® is a broad-spectrum antibiotic that is approved by the United States Food and Drug Administration (FDA) for the following indications:

1. Seromycin® is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.
2. Seromycin® may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially Enterobacter spp. And Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria.
3. Use of Seromycin® in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.

The current product insert for Seromycin® is available on this web site and provides complete information about the clinical pharmacology, indications, contraindications, warnings, precautions, adverse reactions, overdosage treatment, dosage and administration, and how the drug is supplied.

The current supply of Seromycin® was manufactured by Eli Lilly and Company transferred the control of the Chao Center in December, 200, along with the registered trademark and responsibility for the manufacture and sale of this prescription drug in the United States and its territories. The Chao Center received approval from the FDA to manufacture Seromycin under its own label using the same process transferred by Eli Lilly and Company.